Proprietary Technologies at GRG Therapeutics

In Vivo CAR T Cell Therapy

​

Our in vivo CAR T cell therapy technology represents a significant advancement over traditional ex vivo methods. This approach involves directly modifying T cells within the patient’s body, eliminating the need for cell extraction and laboratory manipulation. The benefits of our in vivo CAR T cell therapy include:

• Enhanced Therapeutic Efficacy: Direct in vivo modification allows for a more robust and sustained immune response, as CAR T cells proliferate and target disease cells more effectively.

• Streamlined Treatment Process: By avoiding complex ex vivo procedures, our technology reduces the overall treatment time and cost, making it more accessible to patients.

• Improved Patient Comfort: This less invasive approach minimizes physical burdens on patients, improving their overall treatment experience.

Advanced Genome Editing

​

Our proprietary genome editing technology is a cornerstone of our therapeutic platform. This advanced technique allows us to achieve precise modifications to T cells, ensuring high specificity and minimal off-target effects. Key features of our genome editing technology include:

• High Precision and Specificity: Our technology targets specific genetic sequences with unparalleled accuracy, enhancing the safety and effectiveness of our therapies.

• Reduced Immunogenicity: By minimizing off-target effects, we reduce the risk of adverse immune reactions, ensuring a safer treatment for patients.

• Versatility: Our genome editing platform can be adapted to target a wide range of autoimmune diseases, providing tailored treatment options for various conditions.